Oral Communications

Tue, Nov 17, 2026 · 9:35–10:35 AM EST Ballroom - 4th floor, Boston Marriott Copley Place

About this session

Oral communications: OC7 Efficacy and Safety of Remlifanserin in Patients With Alzheimer's Disease Psychosis; OC8 Clinical Evidence for Disease Modification by Amyloid-Targeting Antibodies; OC9 Topline results from the Phase 2b PRImus-AD trial: Safety and efficacy of oral PRI-002 in early AD; OC10 Sex Differences in Plasma p-tau217, Amyloid-β, and Tau-PET in Cognitively Unimpaired Adults from the AHEAD International Screening Cohort.

Speakers

Lon Schneider

USC Keck School of Medicine

Chair
Sandrine Andrieu

Toulouse University Hospital and INSERM 1295

Chair